Previous history of malignant disease does not preclude entry if the expectation of relapse-free survival at 10 years is 75% or greater
Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up
STEP I: Prior systemic glucocorticoid use for the treatment of non-malignant disorders is permitted; prior or concurrent topical or localized glucocorticoid therapy to treat non-malignant comorbid disorders is permitted
Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up
Recurrent or multifocal malignant gliomas
Patients must have had cytology within 21 days prior to registration; cytology for patients with CIS component is not expected to be negative for malignant cells; if the cytology for patients with only Ta/T1 disease is positive for malignant cells, patient must have had a biopsy of the prostatic urethra within the previous six months
Any evidence of tumor metastasis or co-existing malignant disease
Malignant disease, other than that being treated in this study.
Other malignant diseases than the ones being treated in this study
Malignant disease, other than that being treated in this study.
Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up
Malignant CNS disease that has not been definitively treated
Malignant disease, other than that being treated in this study
Patients with malignant disease other than that being treated in the study.
Participants may have underlying malignant or non-malignant hematologic disease, except for primary immunodeficiency, as the indication for their allogeneic HSCT; patients with immune dysregulation syndromes such as familial or secondary hemophagocytic lymphohistiocytosis (HLH) are eligible
Known distant metastatic disease (e.g. pulmonary or hepatic metastases)\r\n* Subjects with malignant lymphadenopathy in the abdomen or pelvis considered appropriate for radical cystectomy and lymphadnectomy with the goal of complete resection of all malignant disease are allowed
Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years
Non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude any of the study drugs
Systemic antineoplastic therapy or radiotherapy for other malignant conditions within 14 days before the first dose of any study drug
Progressive underlying malignant disease or any post-transplant lymphoproliferative disease
Concurrent, malignant disease for which patient is on active therapy
A history of pneumonitis or extensive bilateral lung disease of non-malignant etiology.
All malignant disease must be able to be encompassed within a single irradiation field
Less than 5% malignant cells in the peripheral blood leukocytes
More than one concurrent, malignant disease
Visible additional disease that suggests a greater than T2 malignant melanoma
Patients with malignant glioma, malignant peripheral nerve sheath tumor, or other malignancy requiring treatment in the last 12 months
Systemic antineoplastic therapy or radiotherapy for other malignant conditions within 14 days before the first dose of any study drug, except for hydroxyurea
Active malignant relapse
Another primary malignant disease, which requires systemic treatment (chemotherapy or radiation)
Less than 5% malignant cells in the peripheral blood leukocytes
Malignant disease other than that being treated in this study.
These procedures are commonly performed in patients with malignant neoplasms, malignant neuroendocrine tumors, or carcinomas in situ, and are commonly “tracked” by hospitals and cancer centers participating in the ACS NSQIP Procedure Targeted option because they are often associated with higher rates of postoperative morbidity and mortality (compared to other, less complex cancer procedures)
Cohort 1: Any solid malignant tumor.
INCLUSION CRITERIA FOR ENROLLMENT: Expectation of ability to safely undergo salvage treatment appropriate for the patient’s malignant disease type
INCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: Expectation of ability to safely undergo salvage treatment appropriate for the patient’s malignant disease type
patients with a history of malignant tumor who have been disease free for at least five years and are not currently being treated.
Patient is diagnosed with benign or malignant stricture, fistula, perforation, or leak
Must not have an advanced malignant hepatic tumor
Histologic proof of phyllodes tumor of borderline or malignant grade, as first defined by Pietruszka and modified by Azzopardi and adopted by the World Health Organization:\r\n * Borderline malignant: 5-9 mitoses/10 high-power fields (HPF), pushing or infiltrating margins, 2+ (moderate) stromal cellularity and atypia\r\n * Malignant: 10 or more mitoses/10 HPF, predominantly infiltrating margins, usually 3+ (severe) stromal cellularity and atypia but occasionally 2+
INCLUSION CRITERIA FOR CCT: patients must have the diagnosis of malignant chromaffin cell tumor (CCT) i.e. malignant pheochromocytoma or malignant paraganglioma
Malignant disease, other than that being treated in this study
Patients with M1 stage according to the Tumor, Node and Metastasis Classification of Malignant Tumours (TNM)
Patients with a history of cancer that has been completely treated, with no evidence of malignant disease currently cannot be enrolled in the study if their chemotherapy was completed less than 6 months prior and/or have received a bone marrow transplant less than 2 years before the first day of study treatment
Systemic antineoplastic therapy or radiotherapy for other malignant conditions within 14 days before the first dose of any study drug, except for hydroxyurea
Presence or history of a malignant disease other than the study related cancer
Subjects diagnosed with other malignant primary tumor
Another primary malignant disease, which requires systemic treatment (chemotherapy or radiation)
Malignant disease, other than that being treated in this study.
In addition, patients with NF1 and with malignant peripheral nerve sheath tumor (MPNST)
Progressive malignant disease, including post-transplant lymphoproliferative disease unresponsive to therapy
Recurrent malignant gliomas
Other non-malignant systemic disease that would preclude treatment with any of the treatment regimens or would prevent required follow-up
A prospective patient for allogeneic hematopoietic stem cell transplant (HSCT) for hematologic conditions, both malignant and non-malignant; donor can be unrelated marrow or peripheral blood cells; a patient with history of central nervous system (CNS) involvement is eligible if CNS disease is in remission at time of study consideration
Existing non-malignant disease that would preclude the administration of pasireotide
Patients with any non-malignant intercurrent illness (e.g. cardiovascular, pulmonary, central nervous system disease) which is either poorly controlled with currently available treatment, or which is of such severity that the investigators deem it unwise to enter the patient on protocol
Epithelioid malignant peripheral nerve sheath tumor
Epithelioid malignant peripheral nerve sheath tumor
Prior or concurrent topical or localized glucocorticosteroid therapy to treat non-malignant comorbid disorders is permitted
Cytogenetic abnormalities finding in malignant myeloma clone with t(4; 14); and / or del(17p); and / or 1q amplification; and / or t(14:16);or
Cytogenetic abnormalities finding in malignant myeloma clone with t(4; 14); and / or del(17p); and / or 1q amplification; and / or t(14; 16); or
Diagnosis of malignant disease within the previous 12 months
Prior or concurrent malignant disease unless cured for more than five years.
Non-malignant neurological disease that would interfere with evaluation of symptoms or signs of brain metastases
Systemic antineoplastic therapy or radiotherapy for other malignant conditions within 12 months before the first dose of any study drug, except for hydroxyurea.
Any other malignant disease
Concurrent, malignant disease for which patient is on active therapy
Malignant disease, other than that being treated in this study
Evidence of recurrent or progressive underlying malignant disease
Evidence of recurrent or progressive underlying malignant disease
Uncertain diagnosis of melanoma i.e. so-called 'melanocytic lesion of unknown malignant potential'.
Active malignant relapse
Participants with active malignant relapse or recrudescence of their prior hematologic disorder
Extension of malignant disease into the anal canal
Progressive underlying malignant disease including post-transplant lymphoproliferative disease.
Patients with malignant glioma, malignant peripheral nerve sheath tumor, or other malignancy requiring treatment in the last 12 months
Patients with a history of malignant tumor who have been disease free for at least five years and are not currently being treated.
Known history of malignant hypertension
All malignant disease must be able to be encompassed within a single irradiation field
Any active or prior malignant or pre-malignant condition of the bone marrow, excluding metastasis of the primary malignancy
Prior investigational agents for malignant or non-malignant disease within 4 weeks prior to Day 1
Patient concurrently has another primary malignant disease, which requires systemic treatment (chemotherapy or radiation)
History of malignant peripheral nerve sheath tumor
Progressive malignant disease, including post-transplant lymphoproliferative disease unresponsive to therapy
Known history of malignant hypertension.
Another active primary malignant disease, which requires systemic treatment (chemotherapy or radiation)
12 Known history of malignant hypertension.
Prior gastrectomy (partial or total) for the underlying malignant disease under investigation
Other non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude treatment with any of the treatment regimens or would prevent required follow-up
Does not have any active or prior malignant or pre-malignant condition of the bone marrow, excluding metastasis of the primary malignancy
Documented diagnosis of the following: Myelodysplastic syndrome lasting ? 3 months and < 3 years Disease must not be secondary to treatment with radiotherapy, chemotherapy, and/or immunotherapy for malignant or autoimmune diseases
No other drug treatment for malignant melanoma administered after completing study treatment with trametinib
Evidence of an optic glioma, malignant glioma, malignant peripheral nerve sheath tumor, or other cancer requiring treatment with chemotherapy or radiation therapy
Patients with serious non-malignant disease (e.g. cardiovascular, scleroderma etc.) which would preclude RT
Alkaline phosphatase > 1.5 x ULN (unless due to lymphoma or a non-malignant, non-hepatic cause such as Paget's disease)
Presence of GI disease, malignant tumors or other conditions known to interfere with ADME
Non-malignant disease that would render the patient unsuitable for treatment according to the protocol.
Non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude any of the study drugs
Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years.
Women with non-palpable malignant lesions, requiring image guided localization.
With diagnosis of malignant or benign disease
Is known or suspected to have a (family) history of malignant hyperthermia
Patients undergoing myeloablative allogenic hematopoietic stem cell transplant for any indication (both malignant and non-malignant) are eligible
Malignant pancreatic disease
TRANSPLANT PATIENTS: all patients undergoing planned allogeneic transplant (both malignant and non-malignant diagnoses)
Progressive malignant disease, including post-transplant lymphoproliferative disease unresponsive to therapy
Evidence of active malignant disease
History of neuroleptic malignant syndrome
Active malignant disease relapse
Active malignant relapse
Known malignant primary brain tumor
Known primary benign or malignant hematologic disorder which can cause anemia.
Men with current anal disease diagnosed by a doctor (e.g., condyloma, hemorrhoids, fissures or malignant tumors) will be excluded
Participants must not have evidence of active/recurrent malignant disease for a minimum of 6 months.
Participants must not have evidence of active/recurrent malignant disease for 6 months
Must be underdoing allogeneic or autologous HCT for a malignant or non-malignant disorder
Other concurrent clinically active malignant disease, requiring treatment
Active metastatic cancer in addition to malignant primary brain tumor
Prior treatment of the prostate gland for malignant conditions (surgery, cryotherapy, radiotherapy, or photodynamic therapy)
Patient is considered a poor risk for surgery due to non-malignant systemic disease (cardiovascular, renal, etc.) that would preclude the treatment options
Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up
